Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial

Patrick J. Grohar, Rachel Heise, Mary Frances Wedekind, Karla Ballman, Leo Mascarenhas, Steven G. DuBois, Robert G. Maki, Elissa A. Boguslawski, Jenna M. Gedminas, Elizabeth R. Wilson, Elaine Thomas, Blair Segers, Lea F. Surrey, Cora Ricker, Kelly Klega, Fariba Navid, Gretchen Y. Lam, Stephanie The, Rebecca Kaufman, Ryan D. Roberts, Masanori Hayashi, Esther Mena, Lindsey Overman, Cody Peer, Keith Schmidt, Mark S. Diamond, William D. Figg, Rochelle Bagatell, M. Liza Lindenberg, Peter L. Choyke, Brian D. Crompton, Brigitte C. Widemann, John W. Glod, Theodore W. Laetsch, Denise K. Reinke, Rashmi Chugh

Open source

DOI: 10.1038/s41591-026-04340-7
Published: 2026-04-16
Container: Nature Medicine
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41591-026-04340-7,
  title = {Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial},
  author = {Patrick J. Grohar and Rachel Heise and Mary Frances Wedekind and Karla Ballman and Leo Mascarenhas and Steven G. DuBois and Robert G. Maki and Elissa A. Boguslawski and Jenna M. Gedminas and Elizabeth R. Wilson and Elaine Thomas and Blair Segers and Lea F. Surrey and Cora Ricker and Kelly Klega and Fariba Navid and Gretchen Y. Lam and Stephanie The and Rebecca Kaufman and Ryan D. Roberts and Masanori Hayashi and Esther Mena and Lindsey Overman and Cody Peer and Keith Schmidt and Mark S. Diamond and William D. Figg and Rochelle Bagatell and M. Liza Lindenberg and Peter L. Choyke and Brian D. Crompton and Brigitte C. Widemann and John W. Glod and Theodore W. Laetsch and Denise K. Reinke and Rashmi Chugh},
  year = {2026},
  journal = {Nature Medicine},
  doi = {10.1038/s41591-026-04340-7},
  url = {https://doi.org/10.1038/s41591-026-04340-7}
}

RIS

TY  - JOUR
TI  - Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial
AU  - Patrick J. Grohar
AU  - Rachel Heise
AU  - Mary Frances Wedekind
AU  - Karla Ballman
AU  - Leo Mascarenhas
AU  - Steven G. DuBois
AU  - Robert G. Maki
AU  - Elissa A. Boguslawski
AU  - Jenna M. Gedminas
AU  - Elizabeth R. Wilson
AU  - Elaine Thomas
AU  - Blair Segers
AU  - Lea F. Surrey
AU  - Cora Ricker
AU  - Kelly Klega
AU  - Fariba Navid
AU  - Gretchen Y. Lam
AU  - Stephanie The
AU  - Rebecca Kaufman
AU  - Ryan D. Roberts
AU  - Masanori Hayashi
AU  - Esther Mena
AU  - Lindsey Overman
AU  - Cody Peer
AU  - Keith Schmidt
AU  - Mark S. Diamond
AU  - William D. Figg
AU  - Rochelle Bagatell
AU  - M. Liza Lindenberg
AU  - Peter L. Choyke
AU  - Brian D. Crompton
AU  - Brigitte C. Widemann
AU  - John W. Glod
AU  - Theodore W. Laetsch
AU  - Denise K. Reinke
AU  - Rashmi Chugh
PY  - 2026
JO  - Nature Medicine
DO  - 10.1038/s41591-026-04340-7
UR  - https://doi.org/10.1038/s41591-026-04340-7
ER  -

APA

Grohar, P. J., Heise, R., Wedekind, M. F., Ballman, K., Mascarenhas, L., DuBois, S. G., Maki, R. G., Boguslawski, E. A., Gedminas, J. M., Wilson, E. R., Thomas, E., Segers, B., Surrey, L. F., Ricker, C., Klega, K., Navid, F., Lam, G. Y., The, S., Kaufman, R., Roberts, R. D., Hayashi, M., Mena, E., Overman, L., Peer, C., Schmidt, K., Diamond, M. S., Figg, W. D., Bagatell, R., Lindenberg, M. L., Choyke, P. L., Crompton, B. D., Widemann, B. C., Glod, J. W., Laetsch, T. W., Reinke, D. K., & Chugh, R. (2026). Trabectedin and low-dose irinotecan to target EWS::FLI1 in Ewing sarcoma: a phase 1/2 trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04340-7

Source records

crossref · retrieved 2026-09-25T20:02:47.108Z